Related references
Note: Only part of the references are listed.Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
Sebastian Bauer et al.
CLINICAL CANCER RESEARCH (2021)
Promoting Inclusion of Members of Racial and Ethnic Minority Groups in Cancer Drug Development
Lola Fashoyin-Aje et al.
JAMA ONCOLOGY (2021)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Andrea Napolitano et al.
BRITISH JOURNAL OF CANCER (2019)
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Cesar Serrano et al.
BRITISH JOURNAL OF CANCER (2019)
Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database
Mark B. Ulanja et al.
JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES (2019)
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri et al.
Journal of the National Comprehensive Cancer Network (2017)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
Jayesh Desai et al.
CLINICAL CANCER RESEARCH (2007)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins
BEC Plaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
